Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

doi:10.1016/S0140-6736(22)01656-7

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	1305-1320
页数	16
期刊	The Lancet
卷	400
期	10360
DOI	https://doi.org/10.1016/S0140-6736(22)01656-7
出版状态	已出版 - 10月 15 2022
已对外发布	是

!!!ASJC Scopus Subject Areas

一般医学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/S0140-6736(22)01656-7

其它文件与链接

指纹

探究 'Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales' 的科研主题。它们共同构成独一无二的指纹。

引用此

@article{dade91e6b58d4816975ec818cce97467,

title = "Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license",

year = "2022",

month = oct,

day = "15",

doi = "10.1016/S0140-6736(22)01656-7",

language = "English",

volume = "400",

pages = "1305--1320",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10360",

}

TY - JOUR

T1 - Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters

T2 - pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

PY - 2022/10/15

Y1 - 2022/10/15

UR - http://www.scopus.com/inward/record.url?scp=85139725483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139725483&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)01656-7

DO - 10.1016/S0140-6736(22)01656-7

M3 - Article

C2 - 36244382

AN - SCOPUS:85139725483

SN - 0140-6736

VL - 400

SP - 1305

EP - 1320

JO - The Lancet

JF - The Lancet

IS - 10360

ER -